siRNA GalXC-GYS2
Type 2 Diabetes
Phase 1Active
Key Facts
About Novo Nordisk
Novo Nordisk has established itself as the dominant player in the diabetes and obesity treatment markets through its innovative GLP-1 receptor agonist portfolio. The company's purpose is to drive change to defeat diabetes and other serious chronic diseases, with a robust pipeline spanning multiple therapeutic areas including cardiovascular disease, rare blood disorders, and metabolic diseases. Recent regulatory approvals, including Wegovy HD (semaglutide 7.2 mg) providing 20.7% mean weight loss, demonstrate continued innovation and market expansion. The company maintains a strong financial position and is expanding global access to its treatments through strategic partnerships.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Tirzepatide (Mounjaro) | Eli Lilly | Approved |
| Orforglipron | Eli Lilly | Phase 3 |
| Trulicity (dulaglutide) | Eli Lilly | Approved |
| Forxiga | AstraZeneca | Approved |
| Amylin/semaglutide combination | Novo Nordisk | Phase 3 |
| Lipaglyn | Zydus Lifesciences | Approved |
| LBS-009 | Belite Bio | Preclinical |
| Jentadueto (Linagliptin/Metformin) | Yuhan | Approved |
| Nesina (Alogliptin) | Yuhan | Approved |
| Metformin & Combinations | Ipca Laboratories | Commercial |
| GSBR-1290 | Structure Therapeutics | Phase 2 |
| Metformin | Granules India | Approved/Commercial |